In2C Global Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 12.43%
- Profit Growth -0.97%
- Ebitda -1.82%
- Net Worth 93.78%
- Total Assets 109.46%
About In2C Global Pharma
In2c Global Pharma Private Limited (IGPPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 November 2013 and has a history of 11 years and three months. Its registered office is in Rangareddy, Telangana, India.
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Venkat Cherala and Sridevi Cherala serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233TG2013PTC091166
- Company No.
091166
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at In2C Global Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkat Cherala  | Director | 21-Nov-2013 | Current |
| Sridevi Cherala | Director | 03-Jan-2020 | Current |
Financial Performance of In2C Global Pharma.
In2C Global Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 12.43% increase. The company also saw a slight decrease in profitability, with a 0.97% decrease in profit. The company's net worth Soared by an impressive increase of 93.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of In2C Global Pharma?
In 2020, In2C Global Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Domos Gardening Services Private LimitedVenkat Cherala and Sridevi Cherala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at In2C Global Pharma?
Unlock and access historical data on people associated with In2C Global Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of In2C Global Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped In2C Global Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
